Related Experiment Video
Updated: Jun 23, 2026
Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Stem-cell transplantation in myocardial infarction: a status report
1St. Luke's-Roosevelt Hospital Center, College of Physicians and Surgeons, New York, New York 10025, USA.
Insights
Stem cell therapy shows promise for regenerating heart tissue after myocardial infarction, potentially improving cardiac function and reducing heart failure. Further research is needed to confirm benefits and assess risks like arrhythmias.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Stem Cell Biology
Background:
- Myocardial infarction (MI) is a primary cause of congestive heart failure (CHF) and mortality.
- Current therapies are insufficient to prevent adverse ventricular remodeling post-MI.
- Stem cells offer potential for myocardial regeneration due to their pluripotent nature.
Purpose of the Study:
- To evaluate the potential of stem cell transplantation for myocardial regeneration after MI.
- To assess the impact of stem cells on hemodynamic and neurohormonal effects contributing to CHF.
- To review preclinical and early clinical evidence regarding stem cell therapy for MI.
Main Methods:
- Review of preclinical animal studies investigating stem cell transplantation post-MI.
- Analysis of early phase I clinical trials on stem cell transplantation feasibility and effects.
- Examination of stem cell potential for myocardial regeneration and perfusion improvement.
Main Results:
- Preclinical studies demonstrate myocardial regeneration and improved perfusion, but suggest potential proarrhythmic effects.
- Phase I clinical trials indicate stem cell transplantation is feasible and may benefit ventricular remodeling.
- Stem cells have the capacity to differentiate into cardiomyocytes.
Conclusions:
- Stem cell transplantation is a potential therapeutic strategy for MI, aiming to reverse adverse remodeling and prevent CHF.
- Further randomized clinical trials are essential to determine the clinical benefits and proarrhythmic risks.
- Stem cell therapy holds promise for improving cardiac function post-MI.
Abstract:
Myocardial infarction is the leading cause of congestive heart failure and death in the industrialized world. Current therapy is limited in preventing the progression of ventricular remodeling and congestive heart failure. Recent interest has focused on stem cells, which are undifferentiated and pluripotent cells that can proliferate, potentially self-renew, and differentiate into cardiomyocytes. Myocardial regeneration with stem-cell transplantation is a possible treatment option to reverse the deleterious hemodynamic and neurohormonal effects that occur after myocardial infarction and can lead to congestive heart failure. Various preclinical animal studies show the potential to regenerate myocardium and improve perfusion to the infarct area to improve cardiac function but also suggest that stem cells may have proarrhythmic effects. Early phase I clinical studies indicate that stem-cell transplantation is feasible and may have beneficial effects on ventricular remodeling after myocardial infarction. Future randomized clinical trials will establish the magnitude of the benefit and the effects on arrhythmias after stem-cell therapy.
